相关实验视频

Updated: Sep 19, 2025

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

内皮微RNA-214通过准小鼠的eNOS来赋予 ангиотензинII高血压

Shuzhen Li^1,2,3, Bing Liu^1,2,3, Shuang Kang^1,2,3

¹Department of Nephrology, Children's Hospital of Nanjing Medical University, Nanjing, China.

Kidney & blood pressure research

|June 1, 2025

概括

内皮 miR-214通过准 eNOS 来促进高血压. 这项研究阐明了microRNAs在心血管疾病中的作用,特别是在高血压的情况下.

科学领域:

心血管生物学心血管生物学
分子医学是分子医学.
高血压研究高血压研究

背景情况:

微RNA因其在心血管疾病中的作用而越来越受认可.
miR-214已与高血压有关,但其在内皮细胞中的具体作用尚不清楚.
了解细胞特异性的microRNA功能对于阐明疾病机制至关重要.

研究的目的:

确定内皮细胞特异性miR-214在调节血压中的作用.
调查 miR-214 影响高血压的潜在分子机制.
根据miR-214功能来确定高血压的潜在治疗点.

主要方法:

在高血压小鼠模型和培养的小鼠大动脉内皮细胞 (MAECs) 中检测miR-214水平.
使用miR-214抑制剂,模仿剂和细胞特异性淘汰小鼠 (内皮,光滑肌,管).
采用了各种细胞和分子技术,包括光酶试验,以确定miR-214在Ang II诱导的高血压中的作用.

主要成果:

ангиотензин II (Ang II) 在小鼠和MAEC中显著增加了miR-214水平.
抑制miR-214减弱的Ang II诱导的高血压和增强的eNOS/p-eNOS表达.
内皮细胞特异性的miR-214淘汰赛小鼠表现出抗高血压表型;光滑肌肉或细胞特异性的删除没有影响.
eNOS被证实是内皮细胞中miR-214的直接向基因.

结论:

内皮 miR-214 通过向和降低 eNOS 的调节,促进 Ang II 诱导的高血压.
这项研究阐明了高血压中关键的致病机制,其中包括内皮 miR-214.
这些发现有助于更深入地了解微RNA在心血管疾病进展中的参与.

关键词:

在英格兰,英格兰 II.内皮NO合成酶是内皮NO合成酶.内皮细胞是内皮细胞.在高血压的高血压.在 miR-21414 中.

更多相关视频

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

相关概念视频

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Hypertension II: Pathophysiology

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...